Viking Therapeutics Shares Surge After Obesity Shot Helps Patients Lose Weight
Product·2 articles across 2 outlets·↩ Updated
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Viking Therapeutics Inc. shares surged after its dual-action obesity shot helped patients lose weight and keep it off, even after they cut their dosing schedule in a small, exploratory study.
The positive results from Viking's weight-loss shot led to a significant increase in its stock price, while shares of rivals Eli Lilly and Novo Nordisk fell in response to the news.
Viking TherapeuticsEli LillyNovo Nordisk
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Viking Therapeutics Inc. shares surged after its dual-action obesity shot helped patients lose weight and keep it off, even after they cut their dosing schedule in a small, exploratory study.”
Bloomberg — Viking Soars as Obesity Shot Helps Cut Weight in Small Study“Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial.”
WSJ — Novo Nordisk Shares Surge on New Obesity Drug Results“Viking stock catapulted Tuesday on "stellar" test results for its weight-loss shot, sending shares of rivals Eli Lilly and Novo lower.”
IBD — Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
Earlier versions
- Sep 22, 1:07 PM — Viking Shares Surge as Obesity Shot Helps Patients Lose Weight in Small Study (1/1)